Ko­re­an of­fi­cials launch Han­mi probe in wake of tox re­ports; Prothena CEO Schenk dies

As we re­port­ed late last week, Boehringer In­gel­heim had to do some ex­plain­ing about its abrupt de­ci­sion to can­cel a $730 mil­lion deal with Ko­rea’s Han­mi. The can­cer drug was linked to sev­er­al cas­es of se­vere tox­i­c­i­ty and one death. Now South Ko­re­an of­fi­cials want to check out if there was any han­ky panky around stock trades ahead of the an­nounce­ment, which came right on the heels of an an­nounced pact with Genen­tech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER